Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E. Walsh, William C. Gruber, Kirsten E. Lyke et al.|New England Journal of Medicine|2020Cited by 2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J. Mulligan, Kathrin U. Jansen, Kirsten E. Lyke et al.|Nature|2020Cited by 1.6k
BNT162b vaccines protect rhesus macaques from SARS-CoV-2Annette B. Vogel, Uğur Şahin, Joshua A. Lees et al.|Nature|2021Cited by 755
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3Ann R. Falsey, William C. Gruber, Robert W. Frenck et al.|New England Journal of Medicine|2021Cited by 420
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E. Walsh, William C. Gruber, Robert W. Frenck et al.|medRxiv|2020Cited by 155